MARKET

LEGN

LEGN

Legend Biotech Corp
NASDAQ
32.01
-0.87
-2.65%
After Hours: 31.85 -0.16 -0.50% 18:11 04/04 EDT
OPEN
31.97
PREV CLOSE
32.88
HIGH
32.37
LOW
30.89
VOLUME
1.53M
TURNOVER
--
52 WEEK HIGH
60.87
52 WEEK LOW
30.17
MARKET CAP
5.88B
P/E (TTM)
-33.0648
1D
5D
1M
3M
1Y
5Y
1D
RBC Capital Keeps Their Buy Rating on Legend Biotech (LEGN)
TipRanks · 5h ago
What Does the Market Think About Legend Biotech?
Benzinga · 1d ago
Marks’ Resignation Is a Blow for Biotech Industry, Says RBC Analyst
TipRanks · 4d ago
Biotech stocks slide as Marks resignation seen being negative for sector
TipRanks · 4d ago
Marks resignation ‘not good’ for biotech sector, says RBC
TipRanks · 4d ago
Weekly Report: what happened at LEGN last week (0324-0328)?
Weekly Report · 4d ago
Weekly Report: what happened at LEGN last week (0317-0321)?
Weekly Report · 03/24 09:27
Demystifying Legend Biotech: Insights From 5 Analyst Reviews
Benzinga · 03/17 20:00
More
About LEGN
More
Legend Biotech Corporation is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of cell therapies for oncology and other indications. Its lead product candidate, ciltacabtagene autoleucel (cilta-cel), referred to as LCAR- B38M, is an autologous chimeric antigen receptor (CAR-T) cell therapy that targets the B-cell maturation antigen (BCMA), which is a highly expressed protein in several hematologic malignancies, including multiple myeloma (MM). In addition to cilta-cel, the Company has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It is also engaged in developing an allogeneic gamma delta CAR-T product candidate and an allogeneic CAR-NK product candidate targeting BCMA for MM.
Recently
Symbol
Price
%Change

Webull offers Legend Biotech Corp (ADR) stock information, including NASDAQ: LEGN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LEGN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading LEGN stock methods without spending real money on the virtual paper trading platform.